Illumina to Divest Itself of Cancer-Test Maker Grail

Gene-sequencing company Illumina said Sunday it will divest itself of cancer blood test maker Grail, following Illumina’s loss in its legal battle against U.S. antitrust regulators. Illumina said it will pursue the divestiture through a third-party sale or capital markets transaction, with a goal of completing terms by the middle of next year. The decision represents a victory for antitrust authorities in the U.S. and Europe, and their tougher scrutiny of corporate combinations.